UNIVERSITY OF MINNESOTA
Driven to Discover℠

studyFINDER

MT2023-20: Hematopoietic cell transplant with reduced intensity conditioning and post-transplant cyclophosphamide for severe aplastic anemia and other forms of acquired bone marrow failure.

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: Not specified
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- 0 to 75 years old - diagnosis of Idiopathic Severe Aplastic Anemia (SAA) - see link to clinicaltrials.gov for complete inclusion and exclusion criteria

Exclusion Criteria:

- women who are pregnant, breastfeeding or intending to become pregnant during the study - uncontrolled infection

Conditions & Interventions

Conditions:
Blood Disorders
Keywords:
Clinics and Surgery Center (CSC), Acquired Amegakaryocytic Thrombocytopenia, Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, SA

More Information

Description: Although allogeneic hematopoietic cell transplant (HCT) is standard treatment for severe aplastic anemia, the use of the lower intensity conditioning drugs with a personalized dosing strategy, low dose total body irradiation (TBI) with dosing based on age and bone marrow abnormalities, and use of the drug cyclophosphamide early after transplant is a newer approach. We are studying whether this new approach is safer and more effective than our previous approach.
Study Contact: Christen Ebens - ebens012@umn.edu
Principal Investigator: Christen Ebens
IRB Number: STUDY00021781